PDC*line Pharma, a clinical-stage biotech company developing a new class of immunotherapies for cancers, presented the primary results of its phase I/II clinical trial for PDC*lung01, an innovative ...

Updated Phase 1 data include a 16.3-month median recurrence-free survival (“mRFS”) and 28.9-month median overall survival (“mOS”) from full study ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle ®) technology, today ...

Updated Phase 1 data include a 16.3-month median recurrence-free survival ("mRFS") and 28.9-month median overall survival ("mOS") from full study population Strong correlation observed between mRFS an ...

Cancer immunotherapy is a form of cancer treatment that uses the body’s immune ... This involves high throughput interrogation of tumour antigen and T cell repertoires, and the analysis of mutations ...